PI
NBIX icon

PEAK6 Investments’s Neurocrine Biosciences NBIX Stock Holding History

PEAK6 Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$104K Hold
900
– – ﹤0.01% 2977
2024
Q2 		$124K Sell
900
-17,500
-95% -$2.4M ﹤0.01% 2952
2024
Q1 		$2.54M Buy
18,400
+17,500
+1,944% +$2.39M 0.01% 1253
2023
Q4 		$119K Buy
900
+700
+350% +$80.6K ﹤0.01% 3492
2023
Q3 		$22.5K Buy
+200
New +$21.1K ﹤0.01% 3743
2021
Q2 		– Sell
-2,100
Closed -$204K – 5525
2021
Q1 		$204K Buy
+2,100
New +$220K ﹤0.01% 3909
2020
Q4 		– Sell
-12,900
Closed -$1.24M – 4956
2020
Q3 		$1.24M Sell
12,900
-7,000
-35% -$810K ﹤0.01% 2083
2020
Q2 		$2.43M Sell
19,900
-15,100
-43% -$1.67M 0.01% 1331
2020
Q1 		$3.03M Buy
+35,000
New +$3.43M 0.02% 780
2019
Q1 		– Sell
-400
Closed -$29K – 4369
2018
Q4 		$29K Sell
400
-41,900
-99% -$4.01M ﹤0.01% 3735
2018
Q3 		$5.2M Buy
+42,300
New +$4.8M 0.02% 767

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's NBIX Position: Q1 2024 in Review

PEAK6 Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 3,277 shares — an estimated $448K sold.

PEAK6 Investments first reported a position in NBIX in Q4 2018 and held it in 13 quarters. The position peaked at $4.59M in Q1 2019. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • PEAK6 Investments reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • PEAK6 Investments sold 3,277 Neurocrine Biosciences shares in Q1 2024, an estimated $448K.
  • PEAK6 Investments first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 13 quarters.
  • PEAK6 Investments's Neurocrine Biosciences position peaked at $4.59M in Q1 2019.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.